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Birth weight and body mass index 
z-score in childhood brain tumors:  
A cross-sectional study
Kuan-Wen Wang  1,2,3, Russell J. de Souza3,4, Adam Fleming1,3,5, Donna L. Johnston6,  
Shayna M. Zelcer7, Shahrad Rod Rassekh8, Sarah Burrow9, Lehana Thabane4,10,11,12 &  
M. Constantine Samaan1,2,3,4
Children with brain tumors (CBT) are at higher risk of cardiovascular disease and type 2 diabetes 
compared to the general population, in which birth weight is a risk factor for these diseases. However, 
this is not known in CBT. The primary aim of this study was to explore the association between birth 
weight and body mass measures in CBT, compared to non-cancer controls. This is a secondary data 
analysis using cross-sectional data from the CanDECIDE study (n = 78 CBT and n = 133 non-cancer 
controls). Age, sex, and birth weight (grams) were self-reported, and confirmed through examination 
of the medical records. Body mass index (BMI) was calculated from height and weight measures and 
reported as kg/m2. BMI z-scores were obtained for subjects under the age of 20 years. Multivariable 
linear regression was used to evaluate the relationship between birth weight and BMI and BMI z-score, 
adjusted for age, sex, puberty, and fat mass percentage. Higher birth weight was associated with higher 
BMI and BMI z-score among CBT and controls. In conclusion, birth weight is a risk factor for higher body 
mass during childhood in CBT, and this may help the identification of children at risk of future obesity 
and cardiometabolic risk.
Brain tumors are the most common cause of cancer-related deaths in children1,2. While brain tumors are a heter-
ogeneous group with some fairly aggressive subtypes, advancements in imaging and therapeutic breakthroughs 
have increased the number of children surviving these tumors1,2. This important milestone has been offset by 
the emergence of co-morbidities and premature mortality in survivors3–7. While traditionally reported outcome 
determinants include tumor recurrence and secondary tumors, recent evidence suggests that children with brain 
tumors (CBT) are at higher risk of premature cardiovascular diseases including hypertension, cerebrovascular 
events and type 2 diabetes compared to non-cancer controls8–10. While the mechanisms leading to these car-
diometabolic disorders are not well understood, the combined burden of the tumor and treatment with these 
emerging chronic disorders will increasingly contribute to adverse outcomes in CBT as these survivors live longer 
and get older.
The global obesity epidemic is the main catalyst of cardiometabolic disorders in the general population11–14, 
and the association of obesity with future type 2 diabetes and cardiovascular diseases has been tracked to child-
hood15. Defining the determinants of obesity, cardiovascular disease and diabetes in CBT will permit the prioriti-
zation of children who need early intervention to improve survivors’ quality of life and lifespan.
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Over the past two decades, evidence has validated the role of birth weight as a risk factor for adult obesity 
and cardiometabolic disorders16,17; however, it is unclear if birth weight in CBT is a risk factor for obesity during 
childhood. Given that CBT have excess adiposity in comparison to non-cancer controls18, it may be a poten-
tial early predictor of further adverse cardiometabolic outcomes. In addition, while CBT have similar rates of 
overweight/obesity when compared to non-cancer controls, this still leaves one-in-four CBT in the overweight/
obese category based on body mass measures19. Body mass index (BMI) is the most used screening tool to assess 
obesity risk, and may still be a predictor of future cardiometabolic risk, as these children get older. Therefore, the 
primary aim of this paper was to explore if birth weight is a risk factor for higher body mass in CBT, compared to 
non-cancer controls.
Results
Population characteristics. We included 78 CBT (n = 33 females [42.3%]) and 133 non-cancer controls 
(n = 60 females, [45.1%]) in this study. The characteristics of the study population are shown in Table 1. The two 
groups have similar age, sex, ethnicity, BMI, BMI z-score, and birth weight distribution. However, the control 
group was taller and weighed more than CBT. On the other hand, CBT had higher fat mass percentage (%FM) 
(CBT 25.80 ± 9.60% versus controls 22.40 ± 9.80%, p = 0.01).
Participants born at full-term comprised the largest groups (CBT n = 45 [57.70%]; controls n = 65 [48.90%]). 
More controls were born pre-term (CBT n = 3 [3.80%]; controls n = 21 [15.80%], p = 0.008) while both have 
similar distribution for early-term (CBT n = 10 [12.80%]; controls n = 24 [18.00%], p = 0.32) and late-term (CBT 
n = 20 [25.60%]; controls n = 23 [17.30%], p = 0.15).
The majority of both CBT and controls were born appropriate for gestational age (AGA) (CBT n = 60 
[76.90%]; controls n = 90 [67.70%]). Both groups had a similar distribution for those who were born small for 
gestational age (SGA) (CBT n = 11 [14.10%]; controls n = 12 [9.00%], p = 0.25) while large for gestational age 
(LGA) was more common in controls (CBT n = 7 [9.00%]; controls n = 31 [23.30%], p = 0.009). Maternal gesta-
tional diabetes was reported in two CBT (2.60%) and in one control (0.80%), while preeclampsia was reported in 
five CBT (6.40%) and 10 controls (7.50%).
The majority of the subjects had normal birth weight (CBT n = 62 [79.50%]; controls n = 104 [78.20%]). Six 
CBT (7.70%) and six controls (4.50%) were born with a low birth weight (<2500 grams). High birth weight 
(>4000 grams) was reported in ten CBT (12.80%) and 23 controls (17.30%).
Tumor characteristics and treatments. Brain tumor characteristics and therapeutic modalities 
are reported in Table 2. The most common tumors in this study population were low-grade gliomas (n = 45 
[57.70%]). Brain tumors were equally distributed between supratentorial and infratentorial regions. The treat-
ments used in participants were surgery alone (n = 25 [32.00%]), and a combination of surgery, radiother-
apy, and chemotherapy (n = 24 [30.80%]). Other single treatment options included radiotherapy alone (n = 2 
[2.60%]), and chemotherapy alone (n = 7 [9.00%]). Other combinations of treatment modalities were surgery and 
Variables
Control CBT
p-valueTotal (n = 133) Mean ± SD Total (n = 78) Mean ± SD
Age at enrollment (years) 14.10 ± 2.70 15.10 ± 7.30 0.64
Sex, No. (%)
0.69 Female 60 (45.10) 33 (42.30)
 Male 73 (54.90) 45 (57.70)
Ethnicity, No. (%)
0.26 European 91 (68.40) 59 (75.60)
 Others 42 (31.60) 19 (24.40)
Puberty, No. (%)
0.001 Pre-pubertal 17 (12.80) 24 (30.80)
 Pubertal 116 (87.20) 54 (69.20)
 Height (cm) 162.70 ± 15.00 151.00 ± 25.20 <0.001
 Weight (kg) 60.00 ± 21.40 53.40 ± 24.90 0.007
 BMI (kg/m2) 21.70 ± 4.20 21.40 ± 4.70 0.49
 BMI z-score 0.49 ± 1.10 0.47 ± 1.10 0.92
BMI category, No. (%)
0.62 BMI%ile < 85 or BMI < 25 88 (66.20) 49 (62.80)
 BMI%ile ≥ 85 or BMI ≥ 25 45 (33.80) 29 (37.20)
Fat mass percentage (%) 22.40 ± 9.80 25.80 ± 9.60 0.01
Birth weight (g) 3491.30 ± 487.40 3436.60 ± 516.50 0.43
Pregnancy gestation (weeks) 38.90 ± 2.30 39.90 ± 1.80 0.001
Table 1. Characteristics of study population. Abbreviations: CBT, Children with Brain Tumors; SD, Standard 
Deviation; BMI, Body Mass Index.
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radiotherapy (n = 6 [7.70%]), surgery and chemotherapy (n = 5 [6.40%]), and radiotherapy and chemotherapy 
(n = 1 [1.30%]). Eight CBT (10.20%) were managed conservatively at the time of inclusion in the study.
The association of birth weight and body mass. To explore the association of birth weight with body 
mass, we performed multivariable regression analyses in CBT, adjusted for age, sex, puberty, and %FM. For 
every unit increase in birth weight, BMI increased by 0.18 units (95%CI 0.03,0.33; p = 0.02) in CBT and by 0.17 
units (95%CI 0.07,0.27; p = 0.001) in controls. Similarly, for every unit increase in birth weight, BMI z-score also 
increased by 3.69 units (95%CI 1.12,6.25; p = 0.006) in CBT and by 2.15 units (95%CI 0.75,3.55; p = 0.003) in 
controls.
To determine if the association between birth weight and body mass differs between CBT and controls, an 
interaction term (birth weight*brain tumor status) was introduced (Table 3). Birth weight is associated with body 
mass, and the effect of birth weight on body mass was similar between CBT and controls (BMI β = 0.02; 95% CI 
−0.15, 0.20; p = 0.80; BMI z-score β = 2.02; 95% CI −0.62,4.67; p = 0.13).
Discussion
The emergence of cardiovascular diseases and type 2 diabetes in survivors of childhood brain tumors are likely 
to contribute to adverse prognoses, and there is an urgent need to identify the drivers of these outcomes to miti-
gate their effects on the life span and quality of life. In this study, we demonstrate that birth weight is a risk factor 
for higher body mass in CBT during childhood, and this relationship was similar to that noted in non-cancer 
controls.
Variables No. (%)
Brain tumor type
Non-NF-1, low grade glioma 34 (43.60)
PNET/Medulloblastoma 17 (21.80)
NF-1, low grade glioma 11 (14.10)
CNS germ cell tumors 6 (7.70)
Subependymal giant cell astrocytoma 3 (3.80)
Ependymoma 2 (2.60)
Craniopharyngioma 2 (2.60)
Meningioma 1 (1.30)
Atypical teratoid/rhabdoid tumor 1 (1.30)
Choroid plexus papilloma 1 (1.30)
Brain tumor location
Supratentorial 36 (46.20)
Infratentorial 42 (53.80)
Brain tumor treatments
Surgery 60 (76.90)
Radiotherapy 33 (42.30)
Chemotherapy 37 (47.40)
No treatment 8 (10.30)
Table 2. Brain tumor type, location, and treatments (n = 78). Abbreviations: CNS, Central Nervous System; 
PNET, Primitive Neuroectodermal Tumor; NF-1, Neurofibromatosis Type 1.
BMI
Variables
Main Effect Interaction
Estimated β (95% CI) p-value Estimated β (95% CI) p-value
Birth weight 0.18 (0.09,0.27) <0.001 0.17 (0.06,0.28) 0.003
Brain tumor status −0.03 (−0.04, −0.01) <0.001 −0.11 (−0.73,0.51) 0.73
Interactiona — — 0.02 (−0.15,0.20) 0.80
BMI z-score
Birth weight 2.81 (1.54,4.09) <0.001 2.10 (0.52,3.68) 0.009
Brain tumor status −0.33 (−0.51, −0.14) 0.001 −7.48 (−16.83,1.86) 0.12
Interactiona — — 2.02 (−0.62,4.67) 0.13
Table 3. Interaction analysis of body mass measures and birth weight in CBT and non-cancer controls. 
Abbreviations: CBT, Children with Brain Tumors; BMI, Body Mass Index; CI, Confidence Interval. Models were 
adjusted for age, sex, puberty, fat mass percentage. aThe interaction term was birth weight*brain tumors status 
(yes/no).
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The influence of the in- and ex-utero environments on the risk of obesity and cardiometabolic risk is an 
important determinant of health outcomes, based on evidence from studies in the general population20–22. One of 
the potential early and feasible measures that forecast these outcomes is birth weight.
Birth weight is driven by several factors, including genes that determine body size and growth, and the intra-
uterine environment23. It is estimated that 10–40% of birth weight is driven by genetic factors, with several loci 
identified to suggest genetic links with body weight and mass23,24. In addition, fetal metabolic programing in utero 
in response to the intrauterine environment contributes to cardiometabolic health postnatally through epigenetic 
and other mechanisms25.
The exposure of an embryo to an adverse intrauterine environment and excess metabolic stress leads to the 
re-programming of the metabolic pathways, to adapt to in-utero scarcity or excess of nutrients22,26. Clinically, this 
manifests with infants being born small or large for gestational age27. However, it is likely that at intermediate 
stages of metabolic stress, some babies may have a birth weight within the normal range, but have been exposed 
to an environment that can alter their metabolic trajectory28.
The evidence for the association of certain categories of birth weight with adult BMI and cardiometabolic 
disorders was highlighted in studies from David Barker and the Dutch famine cohort and others, and showed 
that birth weight and maternal-fetal undernutrition was linked to low birth weight that was associated with adult 
obesity and adverse cardiometabolic outcomes29–34.
In addition, the link between birth weight and obesity was highlighted in previous reports showing that those 
born SGA or LGA to be at risk of adult obesity22. However, recent studies report that in those with a birth weight 
that is sometimes within the normal range, or who have high birth weight (>4000 grams), are at risk of adult 
obesity28,35,36. Contrary to previous evidence37–39, some studies did not show linear, J-shaped or U-shaped associ-
ations of birth weight with adult obesity35,36.
Our data show a positive relationship between birth weight and body mass measures in CBT and controls in 
childhood. This is congruent with recent large-scale studies that have provided further evidence of similar results 
in the general pediatric population27,40,41. Birth weight may help identify those CBT who are at risk of adult obe-
sity. Detailed study of growth paths and longer follow-up period are needed to determine if birth weight is a risk 
factor for obesity in CBT as they reach adulthood.
While available evidence suggest that obese children are at risk of becoming obese adults42–44, the association 
between birth weight, childhood BMI and future cardiometabolic risk is more complex45. It has been reported 
that birth weight below 3.4 kg, which is still considered appropriate for gestational age, and high BMI during 
childhood were independently associated with increased risk of coronary heart disease20. The association between 
low birth weight and type 2 diabetes was also reported46,47. The evidence indicates that both birth weight and BMI 
need to be scrutinized in CBT and controls to identify subjects who are at an increased risk of cardiometabolic 
disorders, as they appear to be independently linked to these outcomes.
While the majority of evidence has focused on high (>4000 g) and low (<2500 g) birth weight and its associ-
ation with obesity risk28,35, it is less clear how a normal birth weight affect this trajectory of adult obesity and car-
diometabolic outcomes in CBT. Our data suggest that as weight trends higher while still within the normal range, 
this represents a risk factor for higher body mass. However, more prospective data sets are required to validate 
this observation and its association with cardiometabolic outcomes in CBT.
One of the strengths of our study is the inclusion of non-cancer controls to provide a comparison group. It is a 
strength to have this control group because when all is equal for birth weight between cases and controls, we can 
test the effect of having cancer and therapy on the association between birth weight and BMI.
It has been shown that CBT have increased adiposity early in life post completion of therapy, and are at higher 
risk of cardiovascular diseases and diabetes compared to the general population, despite having similar BMI to 
controls9,18,48. CBT can have disproportionate effects of their tumor and its treatment on cardiometabolic out-
comes at a similar obesity rate, and birth weight may be a potential risk factor for these outcomes18,49,50.
There are several limitations in this study. We did not have sufficient power to determine the association of 
birth weight with young adult BMI, as the number of young adult subjects in our study was small. While we 
demonstrate that birth weight is positively associated with body mass measures in adolescence, our data does 
not distinguish whether this is a result of the expansion of lean body mass or fat mass, as BMI is a measure of 
total body mass. A recent study showed that birth weight was associated with fat-free mass, but not with fat mass 
among children and adolescents51. This will require further clarification in future studies.
This analysis is cross-sectional and therefore it is not clear if subjects were overweight or obese before their 
brain tumor diagnoses. In addition, the data used in the study were collected as a part of the Canadian Study of 
Determinants of Endometabolic Health in Children (CanDECIDE study)52, and this paper is not related to the 
primary study question. Therefore, the study was not designed to answer this question specifically. Prospective 
collection of data from diagnosis onwards and correlating growth data with those from earlier time points may 
help define growth patterns of those survivors at risk of obesity.
In conclusion, cardiometabolic disorders are occurring at a relatively young age in CBT, and are emerging 
as significant morbidities and as potential determinants of longevity5,9,48. Our results suggest that birth weight 
is a risk factor for higher body mass in CBT in the early years post treatment. Future studies need to focus on 
determining the early origins of obesity and cardiometabolic risk in survivors. This will help identify survivors 
who are at particular risk of these complications, and birth weight may be one of the risk markers used to stratify 
cardiometabolic risk in CBT.
Methods
Participants. This secondary data analysis used data that were collected as a part of the CanDECIDE Study. 
This is a cohort study conducted at McMaster Children’s Hospital in Hamilton, Ontario, Canada52,53.
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Briefly, we recruited participants who were 5 years and older, with no history of autoimmune diseases or 
infection, and have not received immunosuppressive therapy for at least 15 days prior to enrollment. Participants 
were consecutively recruited and the study recruitment took place between November 2012-March 2017. The 
Hamilton Integrated Research Ethics Board approved the study, and participants provided written informed con-
sent. The study procedures were carried out in accordance with relevant guidelines and legal regulations.
Clinical Data and Anthropometric measures. The collected data included age, sex, ethnicity, puberty, 
pregnancy gestation, maternal gestational diabetes and preeclampsia, and reported birth weight using standard-
ized questionnaires52,53. While reported birth weight correlates with measured birth weight54, the reported birth 
weight was verified from the medical records. In CBT, we also collected data regarding tumor type, location, 
sidedness and treatment modalities.
Gestation was defined for those born at less than 37 weeks as preterm, between 37–38 + 6/40 weeks as early 
term, 39–40 + 6/40 weeks as full term, and 41–41 + 6/40 weeks as late term gestations55. Normal birth weight was 
defined to be between 2500–4000 grams56. Infants born SGA were defined as those with a birth weight below 
the10th percentile, AGA as 10th-90th percentile, and LGA as above 90th percentile using Canadian reference 
ranges57.
Anthropometric measurements performed included height measured to 0.1 cm using a stadiometer, and 
weight measured using an electronic weighing scale (Seca, USA) and measured to the closest 0.1 kg. BMI was cal-
culated in kg/m2 for all subjects. For those under 20 years of age (CBT n = 62, controls n = 133), BMI percentile 
and BMI z-scores were also obtained based on the Children’s BMI Tool for Schools58 and the Centers for Disease 
Control and Prevention (CDC) growth chart59, respectively. Subjects with BMI ≥ 85th –<95th percentile were 
classified as overweight, and those above 95th percentile were classified as obese60.
Adiposity was determined by measuring fat mass percentage (%FM) using the Tanita body fat monitor (Tanita 
Corporation, Illinois, USA) for those under 18 years of age, and with the InBody520 body composition analyzer 
(Biospace Co., Ltd, Korea) for those 18 years and older as previously reported18.
Statistical Analysis. All analyses were performed using PASW version 18 statistical package61. 
Kolmogorov-Smirnov test was used to assess the normality of data distribution, and data were log-transformed 
if they were non-normally distributed. Outliers were examined with box plot and visual inspection of extreme 
values. Multiple imputations was done for missing data62. Mean and standard deviation (SD) were reported for 
continuous variables, while the categorical variables were reported as counts with percentages. Independent sam-
ple t-tests were used to compare continuous variables between CBT and non-cancer controls while chi-square 
tests were performed to compare categorical variables.
To explore the association between birth weight and body mass measures in CBT, multivariable linear regres-
sion analysis was performed in this group. The dependent variables included BMI and BMI z-scores in separate 
models. The independent variables included birth weight, age, sex, puberty, and %FM.
The relationship between birth weight and body mass in CBT and non-cancer controls was explored by adding 
an interaction term (birth weight*brain tumor status). Both CBT and non-cancer controls were included in the 
regression analysis.
Results were presented as estimated β coefficients, 95% confidence intervals (CI), and associated p-value. The 
criterion for statistical significance was set at alpha = 0.05.
Data availability. The dataset used for statistical analysis for the current study is available from the corre-
sponding author.
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